» Subscribe Today!
The Power of Information
Home
The Ledger - EST. 1978 - Nashville Edition
X
Skip Navigation LinksHome > Name & Property Search

Name & Property Search

Search results for 'Astrazeneca' | Search again
DeSoto Public Records:0
Shelby Public Records:3
Editorial:14
West Tennessee:0
Middle Tennessee:1
East Tennessee:0
Other:0

You must be a subscriber to see the full results of your search.

Please log in or subscribe below if you are not already a subscriber.

TNLedger Knoxville Edition subscribers get full access to more than 13 million names and addresses along with powerful search and download features. Get the business leads you need with powerful searches of public records and notices. Download listings into your spreadsheet or database.

Learn more about our services | Search again

Editorial Results (free)

1. Group with consumer-friendly vibe pushes drugmakers' message - Friday, March 15, 2019

WASHINGTON (AP) — As ominous music plays in the background, the narrator of a radio ad warns that a Trump administration proposal to apply international pricing to certain Medicare drugs would be a nightmare for seniors.

2. Senators draw on own experiences to chastise drug companies - Friday, February 22, 2019

WASHINGTON (AP) — Channeling the ire of constituents and drawing from personal experience, senators chastised drug company executives Tuesday over the high cost of prescription medications, while the CEOs warned that government price controls could stifle breakthroughs on diseases like Alzheimer's.

3. Brexit uncertainty set to hobble UK economy through winter - Friday, October 12, 2018

LONDON (AP) — The uncertainty over Brexit that's hobbling the British economy is set to go on for longer than expected, leaving companies and households in a limbo.

When Britain triggered the two-year timetable to leave the European Union, October's summit of EU leaders was supposed to be the moment a Brexit deal would be agreed on to give parliaments the time to pass it into law ahead of March's departure.

4. AP finds climate change risk for 327 toxic Superfund sites - Friday, December 22, 2017

TARPON SPRINGS, Fla. (AP) — Anthony Stansbury propped his rusty bike against a live oak tree and cast his fishing line into the rushing waters of Florida's Anclote River.

When he bought a house down the street last year, Stansbury says he wasn't told that his slice of paradise had a hidden problem. The neighborhood is adjacent to the Stauffer Chemical Co. Superfund site, a former chemical manufacturing plant that is on the list of the nation's most polluted places. That 130-acre lot on the river's edge is also located in a flood zone.

5. Allergan, Pfizer call off proposed $160B merger - Friday, April 1, 2016

The biggest U.S.-based drugmaker, Pfizer Inc., will stay put thanks to aggressive new Treasury Department rules that succeeded in blocking Pfizer from acquiring rival Allergan and moving to Ireland — on paper — to reduce its tax bill.

6. Pfizer, Allergan $160B deal forms world's largest drugmaker - Friday, November 20, 2015

Pfizer and Allergan are joining in the biggest buyout of the year, a $160 billion stock deal that will create the world's largest drugmaker.

It's also the largest so-called inversion, where an American corporation combines with a company headquartered in a country with a lower corporate tax rate, saving potentially millions each year in U.S. taxes.

7. Health care, energy stocks among gainers on Wall Street - Friday, January 30, 2015

NEW YORK (AP) — U.S. stocks rose broadly Thursday, helped by a 6 percent jump in the price of oil and a rise in health care stocks following Pfizer's $16 billion deal to buy drugmaker Hospira.

8. Europe, Syria drag on global stock markets - Friday, September 19, 2014

NEW YORK (AP) — Grim economic news from Europe and airstrikes in Syria rattled global stocks Tuesday.

Most of the damage was felt in European markets, which fell sharply after a closely watched gauge of business activity for the region fell to a nine-month low.

9. Late push leaves US stock market mostly higher - Friday, April 25, 2014

NEW YORK (AP) — Stocks are ending a choppy day mostly higher as investors balanced enthusiasm over a possible merger in the health care industry with bad news from Bank of America.

The Dow Jones industrial average rose 87 points, or 0.5 percent, to close at 16,448 Monday.

10. Technology, bank stocks drag US market lower - Friday, April 25, 2014

NEW YORK (AP) — Stocks mostly fell Monday afternoon, led by declines in technology and bank stocks, as investors' excitement about a potential blockbuster pharmaceutical deal was snuffed out.

11. Vanderbilt's earnings from tech on rise - Friday, October 11, 2013

NASHVILLE (AP) — Vanderbilt University officials say earnings from technology commercialization has more than quadrupled in the past three years, bringing in more than $24.5 million in the 2013 fiscal year.

12. Weak Oracle sales, Cyprus fears weigh on US shares - Friday, March 15, 2013

Stocks fell on Wall Street Thursday as Oracle's weak sales results weighed down big U.S. technology companies. Traders worried about Cyprus running out of time to avoid bankruptcy.

Major indexes followed European markets lower at the open. The Dow Jones industrial average fell as much as 98 points. By mid-day they had pared the losses. Shortly before noon eastern time, the Dow Jones industrial average and the Standard & Poor's 500 index were down about 0.3 percent. The Nasdaq composite index, which is heavily weighted toward tech shares, declined more than 0.6 percent.

13. Pharma's niche focus spurs US aid for antibiotics - Friday, January 20, 2012

WASHINGTON (AP) — The pharmaceutical industry won approval to market a record number of new drugs for rare diseases last year, as a combination of scientific innovation and business opportunity spurred new treatments for diseases long-ignored by drug companies.

14. With new generic rivals, Lipitor's sales halved - Friday, December 16, 2011

TRENTON, N.J. (AP) — Sales of cholesterol blockbuster Lipitor plunged by half barely a week after the world's top-selling drug got its first U.S. generic competition, new data show.

That's despite a very aggressive effort by Lipitor maker Pfizer Inc. to keep patients on its pill, which generated peak sales of $13 billion a year, through patient subsidies and big rebates to insurers.